Syndax Pharmaceuticals (SNDX)
$19.29
Live
Performance
- $19.12$19.64$19.29
0.88%
Downside
Day's Volatility :2.65%
Upside
1.78%
- $11.22$25.34$19.29
41.86%
Downside
52 Weeks Volatility :55.74%
Upside
23.88%
Returns
| Period | Syndax Pharmaceuticals | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -15.73% | 3.6% | 0.0% |
6 Months | -5.96% | 10.2% | 0.0% |
1 Year | 73.05% | 19.6% | 0.0% |
3 Years | 5.74% | 16.8% | -23.0% |
Highlights
Market Capitalization | 1.7B |
Book Value | $5.11 |
Earnings Per Share (EPS) | -3.4 |
PEG Ratio | 0.0 |
Wall Street Target Price | 35.42 |
Profit Margin | 0.0% |
Operating Margin TTM | -2120.46% |
Return On Assets TTM | -39.63% |
Return On Equity TTM | -63.3% |
Revenue TTM | 3.5M |
Revenue Per Share TTM | 0.05 |
Quarterly Revenue Growth YOY | 33297.4% |
Gross Profit TTM | 139.7M |
EBITDA | -288.0M |
Diluted Eps TTM | -3.4 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.75 |
EPS Estimate Next Year | -3.24 |
EPS Estimate Current Quarter | -0.91 |
EPS Estimate Next Quarter | -1.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 83.62%
Technicals Summary
Sell
Neutral
Buy
Syndax Pharmaceuticals is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Syndax Pharmaceuticals | 9.93% | -5.96% | 73.05% | 5.74% | 191.14% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Syndax Pharmaceuticals | 0.0 | NA | 0.0 | -3.75 | -0.63 | -0.4 | NA | 5.11 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Syndax Pharmaceuticals | Buy | $1.7B | 191.14% | 0.0 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Syndax Pharmaceuticals
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 11.7%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 39.1%
Institutional Holdings
BlackRock Inc
9.29%Wellington Management Company LLP
8.62%Kynam Capital Management, LP
6.72%Vanguard Group Inc
5.64%venBio Select Advisor LLC
4.57%State Street Corp
4.26%
Company Information
syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.
Organization | Syndax Pharmaceuticals |
Employees | 184 |
CEO | Mr. Michael A. Metzger M.B.A. |
Industry | Health Technology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$19.29
-2.13%
Invesco Bulletshares 2025 Hi
$19.29
-2.13%
Schwab International Dividend Equity Etf
$19.29
-2.13%
Blockchain Coinvestors Acquisition Corp.
$19.29
-2.13%
Allgiant Travel Company
$19.29
-2.13%
Rogers Corp
$19.29
-2.13%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$19.29
-2.13%
Iheartmedia
$19.29
-2.13%
Lightpath Technologies Inc
$19.29
-2.13%